Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod for myasthenic crisis
MOH_2024-04-15_013374Phase 4Not yet recruiting
- Sponsor
- ד"ר שחר שלי
- Start
- Apr 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of efgartigimod alfa in myasthenia gravis (MG) (2 arms), sponsored by ד"ר שחר שלי. Primary endpoint: Change in MG-ADL score. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on MOH_2024-04-15_013374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-15_013374.